Andre van der Westhuizen

Andre van der Westhuizen

Auto-generated profile, based on publicly available information

Andre van der Westhuizen

Calvary Mater Hospital, Newcastle, Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JWJeffrey S. Weber
Jeffrey S. Weber
DSDirk Schadendorf
Dirk Schadendorf
MVMichele Del Vecchio
Michele Del Vecchio
JLJames Larkin
James Larkin
VAVictoria Atkinson
Victoria Atkinson
GLGeorgina Venetia Long
Georgina Venetia Long
PURPOSE: Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma. PATIENTS AND METHODS: In this randomized, double-blind, phase III trial, 1,833 patients received nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks (916 patients) or nivolumab 480 mg once every 4 weeks (917 patients) for ≤ 1 year. After random assignment, patients were stratified by tumor programmed death ligand 1 (PD-L1) expression and stage. Dual primary end points were recurrence-free survival (RFS) in randomly assigned patients and in the tumor PD-L1 expression-level < 1% subgroup. RESULTS: At a minimum follow-up of approximately 23.7 months, there was no significant difference between treatment groups for RFS in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14). In all patients, 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab). Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group. Treatment-related deaths were reported in 0.4% of patients in the combination group and in no nivolumab-treated patients. CONCLUSION: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma. Nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment.

1 January 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
MCmarco colleoni
marco colleoni
WLWeixiu Luo
Weixiu Luo
PKPer Karlsson
Per Karlsson
JCJacquie Chirgwin
Jacquie Chirgwin
SAStefan Aebi
Stefan Aebi
DZDimitrios Zardavas
Dimitrios Zardavas

1 February 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
RDRyan J. Davey
Ryan J. Davey
AWAndre van der Westhuizen
Andre van der Westhuizen
NBNikola A. Bowden
Nikola A. Bowden

30 September 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
JBJohanna C. Bendell
Johanna C. Bendell
TSTamara Sauri
Tamara Sauri
AGAntonio Cubillo Gracián
Antonio Cubillo Gracián
RARafael Alvarez
Rafael Alvarez
CLCARLOS LOPEZ LOPEZ
CARLOS LOPEZ LOPEZ
FGfor the McCAVE Study Group
for the McCAVE Study Group
Background. Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) versus bevacizumab/mFOLFOX‐6 for first‐line mCRC. Patients and Methods. All patients received mFOLFOX‐6 and were randomized 1:1 to also receive vanucizumab 2,000 mg or bevacizumab 5 mg/kg every other week. Oxaliplatin was given for eight cycles; other agents were continued until disease progression or unacceptable toxicity for a maximum of 24 months. The primary endpoint was investigator‐assessed PFS. Results. One hundred eighty‐nine patients were randomized (vanucizumab, n = 94; bevacizumab, n = 95). The number of PFS events was comparable (vanucizumab, n = 39; bevacizumab, n = 43). The hazard ratio was 1.00 (95% confidence interval, 0.64–1.58; p = .98) in a stratified analysis based on number of metastatic sites and region. Objective response rate was 52.1% and 57.9% in the vanucizumab and bevacizumab arm, respectively. Baseline plasma Ang‐2 levels were prognostic in both arms but not predictive for treatment effects on PFS of vanucizumab. The incidence of adverse events of grade ≥3 was similar between treatment arms (83.9% vs. 82.1%); gastrointestinal perforations (10.8% vs. 8.4%) exceeded previously reported rates in this setting. Hypertension and peripheral edema were more frequent in the vanucizumab arm. Conclusion. Vanucizumab/mFOLFOX‐6 did not improve PFS and was associated with increased rates of antiangiogenic toxicity compared with bevacizumab/mFOLFOX‐6. Our results suggest that Ang‐2 is not a relevant therapeutic target in first‐line mCRC. Implications for Practice. This randomized phase II study demonstrates that additional angiopoietin‐2 (Ang‐2) inhibition does not result in superior benefit over anti–VEGF‐A blockade alone when each added to standard chemotherapy. Moreover, the performed pharmacokinetic and pharmacodynamic analysis revealed that vanucizumab was bioavailable and affected its intended target, thereby strongly suggesting that Ang‐2 is not a relevant therapeutic target in the clinical setting of treatment‐naïve metastatic colorectal cancer. As a result, the further clinical development of the dual VEGF‐A and Ang‐2 inhibitor vanucizumab was discontinued.

1 July 2015 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
CGCraig Gedye
Craig Gedye
AWAndre van der Westhuizen
Andre van der Westhuizen
TJTom John
Tom John

1 August 2020 in Clinical Oncology
Verified
Journal Article
Closed access
MWMichelle Wong-Brown
Michelle Wong-Brown
AWA. van der Westhuizen
A. van der Westhuizen
NBNikola A. Bowden
Nikola A. Bowden